Our expectations on when we will be eating cultured meatWhen will we be eating cultured meat? In this blog we tell you our expectations.Cultured meat companies have been optimistic in social media about when they will be able to enter the market. Years have passed by,...
Will we be eating cultured meat soon? The data is telling us different storiesIn this blog we dive deeper into the projections of several market reports. How do these projections relate to the market entry of cultured meat?Introduction Although several companies have...
These are the companies that will drive cultured meat to our plateThe biggest challenge for the cultured meat companies is the scale-up of the production and reduction of production costs. ttopstart helps these companies in developing smart strategies to achieve their...
Examples of biotech IPOs that quickly went public2020 was a record year for biotech Initial Public Offering (IPOs), with over 100 IPOs raising an aggregate $12B– nearly doubling the number of IPOs and the aggregate proceeds recorded in 2019. In this article we show...
Part I: How to successfully commercialise a molecular diagnostic productFor diagnostic companies to successfully commercialise their first product, they will have to navigate through a plethora of decisions that are essential to enable market entry. To enable these...
ttopstart introduces corporate finance services for the Life Science and Health sectorttopstart introduces corporate finance services specifically designed for Life Science and Healthcare sector. The number of biomedical innovations that eventually reach the patient...
The vicious circle of antibiotics market decay explainedGlobal antibiotic stewardship measures are critical in our fight against antibiotic resistant bacteria. These well-intended measures, however, have played a prominent role in the breakdown of the antibiotics...
Successful autonomous late-stage biotech financing without being eaten Many biotech firms aim for an exit through acquisition by a larger biotech or a pharmaceutical company. But what are the options to fund growth and scale operations (including financing later-stage...
Why the antibiotics market needs to be fixedWe are still in the middle of the COVID-19 crisis, but another potentially larger crisis is ahead that threatens our global healthcare system; the anti-microbial resistance (AMR) crisis. Whilst we weren’t ready for COVID-19,...
AI solutions in healthcare: the challenge of the complicated reimbursement system ttopstart's series on AIIn our series of articles about artificial intelligence (AI) we discuss the biggest opportunities and challenges for scaling and implementing AI into life...
Jasper Levink: “AI without a vision is fishing” ttopstart's series on AIIn healthcare, all eyes are on Artificial Intelligence (AI). New AI-driven technologies have the potential to boost personalised medicine, automate laborious tasks and facilitate data-driven...
AI workflow: the 4 components ttopstart's series on AIOne of the unique powers of using artificial intelligence in healthcare is that it can help retrieve and process valuable information, such as quantitative diagnostic characteristics, much faster and potentially...